# Phase 2.5: Sequence Authenticity, Provenance, and Final Dataset Integrity Validation

## 1. Executive Summary & Objective

In **Phase 2.5**, we conducted an independent validation of sequence authenticity, accession-level provenance, deduplication correctness, biological identity, and dataset accounting across the **curated HSV protein sequence dataset** ($N=22,689$).

The objective is to establish that:
1. Every sequence is **authentic and traceable** to its primary authoritative accession (NCBI GenBank, RefSeq, UniProtKB, PDB, PRF, Patent).
2. Preprocessing was **strictly sequence-preserving**: no raw FASTA record was silently discarded, and every raw record was mapped to a canonical sequence or assigned a documented exclusion status ($0$ sequence modifications, $100\%$ exact SHA-256 match).
3. The dataset accounting partition is **100% closed with zero unaccounted sequences**.

> [!IMPORTANT]
> The collection of 22,689 sequences represents the **canonical HSV protein sequence corpus** (encompassing laboratory reference strains, clinical isolates, and sequence fragments). It is not described as a single static "proteome" or claimed to be uniformly full-length or experimentally characterized.

---

## 2. Four Distinct Validation Dimensions

To ensure methodological clarity, the validation is explicitly separated into four distinct dimensions:

```
+-----------------------------------------------------------------------------------+
|                            FOUR VALIDATION DIMENSIONS                             |
+-----------------------------------------------------------------------------------+
| 1. SEQUENCE_PROVENANCE   : Traceability to raw FASTA headers & primary accessions |
| 2. SEQUENCE_FIDELITY     : 100% exact SHA-256 residue match (0 modifications)     |
| 3. BIOLOGICAL_IDENTITY   : Species confirmation (HSV-1/HSV-2) & gene resolution   |
| 4. TEMPORAL_ANNOTATION   : Kinetic class grounded in primary experimental studies  |
+-----------------------------------------------------------------------------------+
```

---

## 3. Sequence Completeness Breakdown ($N=22,689$)

Sequence completeness is determined directly from the authoritative `completeness_status` field rather than equating annotation tier with sequence length:

| Completeness Status | Total Sequences | Percentage | Tier A | Tier B | Tier C | Tier D | Description |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **`FULL_LENGTH`** | `20,462` | `90.18%` | `10,482` | `9,980` | `0` | `0` | Complete full-length protein coding sequence (CDS) |
| **`PARTIAL_FRAGMENT`** | `1,957` | `8.63%` | `0` | `1,551` | `0` | `406` | Validated biological partial sequence / fragment |
| **`PDB_FRAGMENT`** | `148` | `0.65%` | `0` | `0` | `0` | `148` | Technical crystallization chain / peptide construct |
| **`ENGINEERED_FRAGMENT`**| `55` | `0.24%` | `0` | `0` | `0` | `55` | Recombinant, mutated, or chimeric construct |
| **`UNKNOWN`** | `67` | `0.30%` | `0` | `0` | `5` | `62` | Unresolved length (e.g. taxonomic conflict / unassigned) |
| **Total** | **`22,689`** | **`100.00%`** | **`10,482`**| **`11,531`**| **`5`** | **`671`** | **Exhaustive partition across all tiers** |

> [!NOTE]
> Tier B ($N=11,531$) is composed predominantly of full-length sequences ($9,980$, $86.55\%$) alongside biological partial/fragment sequences ($1,551$, $13.45\%$). Tier B sequences are retained in the curated corpus for representation learning and sensitivity analysis.

---

## 4. Source Database Breakdown ($N=22,689$)

Every sequence in the dataset was retrieved and verified against its authoritative repository:

| Source Database | Total Records | External Sequence Retrieved | Exact Matches | Unavailable | Mismatches |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **NCBI GenBank** | `22,292` | `22,292` ($100\%$) | `22,292` ($100\%$) | `0` | `0` |
| **PDB** | `146` | `146` ($100\%$) | `146` ($100\%$) | `0` | `0` |
| **NCBI RefSeq** | `100` | `100` ($100\%$) | `100` ($100\%$) | `0` | `0` |
| **UniProtKB** | `98` | `98` ($100\%$) | `98` ($100\%$) | `0` | `0` |
| **Patent** | `49` | `49` ($100\%$) | `49` ($100\%$) | `0` | `0` |
| **PRF** | `4` | `4` ($100\%$) | `4` ($100\%$) | `0` | `0` |
| **Total** | **`22,689`** | **`22,689`** ($100\%$) | **`22,689`** ($100\%$) | **`0`** | **`0`** |

---

## 5. Dataset Accounting & Partition Reconciliation

| Category | Sequence Count | Percentage | Description |
| :--- | :--- | :--- | :--- |
| **`SUPERVISED`** | `16,657` | `73.41%` | Biologically retained sequences with evidence-supported Immediate-Early, Early, or Late annotations |
| **`UNKNOWN_ELIGIBLE`** | `5,356` | `23.61%` | Biologically retained uncharacterized viral proteins in curated corpus without experimental temporal evidence |
| **`CONFLICTING`** | `5` | `0.02%` | Cross-file taxonomic conflicts quarantined in manual review queue (Tier C) |
| **`EXCLUDED`** | `671` | `2.96%` | Excluded non-HSV hosts (411), technical PDB chains (147), recombinant mutants (50), synthetic patents (49), unassigned (14) |
| **Total Canonical** | **`22,689`** | **`100.00%`** | Total unique hash-deduplicated canonical sequences in the dataset |
| **Unaccounted** | **`0`** | **`0.00%`** | Zero orphan sequences |

$$\text{Accounting Partition} = \text{Supervised } (16,657) + \text{Unknown Eligible } (5,356) + \text{Conflicting } (5) + \text{Excluded } (671) = \mathbf{22,689}$$

---

## 6. Supervised Dataset Validation ($N=16,657$)

The supervised temporal dataset [final_temporal_supervised_dataset.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/data/processed/final_temporal_supervised_dataset.csv) was independently validated:
- **Canonical Membership**: $16,657 / 16,657$ sequences exist identically in the master corpus.
- **Temporal Class Purity**: Contains only `IMMEDIATE_EARLY` ($1,552$), `EARLY` ($4,140$), and `LATE` ($10,965$).
- **Zero Contamination**: 0 UNKNOWN, 0 CONFLICTING, 0 Excluded.
- **Validation Verdict**: $16,657 / 16,657$ records confirmed **`VALID`** in [phase2_5_supervised_dataset_validation.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_supervised_dataset_validation.csv).

---

## 7. Answers to Mandatory Audit Questions

1. **Are the 22,689 canonical sequences traceable?**
   - **Yes.** 100% of sequences possess traceable primary accessions and original FASTA headers derived from source records.
2. **How many have accession-level provenance?**
   - **22,689** sequences ($100.00\%$).
3. **How many exactly match an authoritative source sequence?**
   - **22,689** sequences ($100.00\%$).
4. **How many are legitimate partial/fragment sequences?**
   - **1,957** partial/fragment sequences ($8.63\%$) plus $148$ PDB and $55$ engineered fragments.
5. **How many have sequence mismatches?**
   - **0** sequences ($0.00\%$).
6. **How many have species conflicts?**
   - **5** sequences ($0.02\%$, quarantined in Tier C).
7. **How many have gene/protein identity conflicts?**
   - **0** conflicting annotations among accepted sequences.
8. **How many are source-unavailable?**
   - **0** records.
9. **Was preprocessing sequence-preserving?**
   - **Yes.** No raw FASTA record was silently discarded. Every raw record was mapped to a canonical sequence or assigned a documented exclusion status.
10. **Does every raw record reconcile to the canonical dataset?**
    - **Yes.** 100% bidirectional mapping between 22,710 raw records and 22,689 canonical sequences.
11. **Does the final supervised dataset contain only valid temporal classes?**
    - **Yes.** 100% of the 16,657 supervised sequences are `IMMEDIATE_EARLY`, `EARLY`, or `LATE`.
12. **Is the dataset accounting internally consistent?**
    - **Yes.** Total canonical count closes to 22,689 with **0 unaccounted sequences**.

---

## 8. Verification Tables & Artifacts

- **Completeness Summary Table**: [phase2_5_completeness_summary.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_completeness_summary.csv)
- **Source Database Summary Table**: [phase2_5_source_database_summary.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_source_database_summary.csv)
- **Dataset Accounting Table**: [phase2_5_dataset_accounting.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_dataset_accounting.csv)
- **Provenance Coverage Table**: [phase2_5_provenance_coverage.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_provenance_coverage.csv) ($N=22,689$)
- **Sequence Authenticity Table**: [phase2_5_sequence_authenticity_verification.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_sequence_authenticity_verification.csv) ($N=22,689$)
- **Verification Summary Table**: [phase2_5_verification_summary.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_verification_summary.csv)
- **Supervised Dataset Validation Table**: [phase2_5_supervised_dataset_validation.csv](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/tables/phase2_5_supervised_dataset_validation.csv) ($N=16,657$)
- **Validation Log Report**: [phase2_5_sequence_validation_report.txt](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/results/logs/phase2_5_sequence_validation_report.txt)
- **Reproducibility Script**: [phase2_5_sequence_authenticity_audit.py](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/scripts/phase2_5_sequence_authenticity_audit.py)
- **Automated Test Suite**: [test_phase2_5_sequence_authenticity.py](file:///c:/Users/shiva/OneDrive/Desktop/HSV1-Proteome-Analysis/HSV_Computational_analysis/tests/test_phase2_5_sequence_authenticity.py)

---

## 9. Stop Condition & Next Phase

> [!IMPORTANT]
> **Phase 2.5 Validation is Final.**
> Sequence authenticity, accession provenance, parsing fidelity, completeness classification, and dataset accounting are validated and frozen.
> 
> Phase 3 (Sequence & Representation Engineering) remains locked and will start only upon explicit instruction.
